Business Context and Reporting Period
Company: Legend Biotech Corporation (LEGN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Legend Biotech is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies, primarily for oncology. Its lead product, CARVYKTI (cilta-cel), is an autologous CAR-T cell therapy for multiple myeloma, developed and commercialized in collaboration with Janssen Biotech, Inc. (Johnson & Johnson). The company operates through subsidiaries in the United States, China, and the European Union.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 (USD Millions) | 2024 (USD Millions) |
|---|---|---|
| Total Revenue | 1,028.9 | 627.3 |
| Net Loss | (296.8) | (177.0) |
| Operating Loss | (136.5) | (309.5) |
| Research & Development Expenses | 414.7 | 413.5 |
| Cash and Cash Equivalents | 901.9 | 286.7 |
| Total Assets | 1,733.7 | 1,670.2 |
| Accumulated Deficit | (1,958.5) | (1,661.7) |
Revenue Composition: Collaboration revenue (profit sharing from CARVYKTI sales) was $944.8 million, representing a 96% increase year-over-year. License and other revenue was $84.1 million, driven by the Novartis License Agreement and related party sublicenses.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $401.6 million (64%) primarily due to a $462.2 million increase in collaboration revenue from CARVYKTI sales.
- Net Loss Increase: Net loss widened by $119.8 million to $296.8 million. This was largely driven by a $276.6 million swing in "Other (Expense)/Income, net," which turned from a $111.8 million gain in 2024 to a $164.8 million expense in 2025 due to unrealized foreign exchange losses ($169.1 million).
- Liquidity Improvement: Cash and cash equivalents increased significantly to $901.9 million from $286.7 million, supported by a net cash inflow from investing activities of $709.6 million (primarily maturities of time deposits).
- Debt Recoupment Trigger: The collaboration with Janssen achieved a profitable position in 2025, triggering the recoupment of $319.1 million in funding advances (principal and interest) from future profits or milestones, classified as a current liability.
Guidance, Outlook, and Risks
Outlook: Management expects expenses to increase significantly in 2026 due to ongoing R&D, manufacturing expansion, and commercialization efforts. The company believes its current cash position ($948.6 million including time deposits) is sufficient to fund operations for at least the next 12 months.
Key Risks and Contingencies:
- Foreign Exchange Volatility: Significant unrealized losses ($169.1 million) were recorded due to fluctuations between the USD and EUR. The company does not currently hedge these exposures.
- Regulatory and Pricing Risks: The company faces risks related to U.S. government "Most Favored Nation" (MFN) pricing strategies and potential price controls in the EU and China. Additionally, the FDA has issued safety warnings regarding secondary hematological malignancies and immune effector cell-associated enterocolitis (IEC-EC) for CARVYKTI.
- China Operations: As a Cayman Islands holding company with significant operations in China, the company faces risks related to PRC regulations on human genetic resources, data privacy, cybersecurity, and potential restrictions on foreign investment in gene therapy technologies.
- Intellectual Property Litigation: On January 5, 2026, 2seventy bio, Inc. (a Bristol-Myers Squibb subsidiary) filed a patent infringement complaint in the Unified Patent Court alleging infringement of a European patent regarding CARVYKTI manufacturing and sales in Europe.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $948.6 million cash position against the projected increase in operating expenses and the $319.1 million Janssen funding advance recoupment obligation.
- FX Exposure: Assess the impact of continued EUR/USD volatility on future earnings, given the lack of hedging strategies.
- Patent Litigation: Monitor the status of the patent infringement lawsuit filed by 2seventy bio, Inc. in the Unified Patent Court and its potential impact on European sales.
- China Regulatory Compliance: Confirm ongoing compliance with PRC regulations regarding human genetic resources (HGR) and data cross-border transfers, which could disrupt clinical trials or operations.
- Manufacturing Capacity: Evaluate the progress of manufacturing expansion in the U.S. and Belgium to meet global demand for CARVYKTI, including reliance on third-party CMOs.